1eby: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 24: | Line 24: | ||
==Reference== | ==Reference== | ||
Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors., Andersson HO, Fridborg K, Lowgren S, Alterman M, Muhlman A, Bjorsne M, Garg N, Kvarnstrom I, Schaal W, Classon B, Karlen A, Danielsson UH, Ahlsen G, Nillroth U, Vrang L, Oberg B, Samuelsson B, Hallberg A, Unge T, Eur J Biochem. 2003 Apr;270(8):1746-58. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/12694187 12694187] | Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors., Andersson HO, Fridborg K, Lowgren S, Alterman M, Muhlman A, Bjorsne M, Garg N, Kvarnstrom I, Schaal W, Classon B, Karlen A, Danielsson UH, Ahlsen G, Nillroth U, Vrang L, Oberg B, Samuelsson B, Hallberg A, Unge T, Eur J Biochem. 2003 Apr;270(8):1746-58. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/12694187 12694187] | ||
Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy., Lindberg J, Pyring D, Lowgren S, Rosenquist A, Zuccarello G, Kvarnstrom I, Zhang H, Vrang L, Classon B, Hallberg A, Samuelsson B, Unge T, Eur J Biochem. 2004 Nov;271(22):4594-602. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/15560801 15560801] | |||
[[Category: HIV-1 retropepsin]] | [[Category: HIV-1 retropepsin]] | ||
[[Category: Human immunodeficiency virus 1]] | [[Category: Human immunodeficiency virus 1]] | ||
| Line 31: | Line 33: | ||
[[Category: Protein-inhibitor complex]] | [[Category: Protein-inhibitor complex]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 10:23:11 2008'' | ||
